 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Karuna Therapeutics, Inc. (NASDAQ:KRTX  Get Free Report)s share price dropped 6.3% on Thursday . The stock traded as low as $195.57 and last traded at $195.59. Approximately 122,778...

Karuna Therapeutics (NASDAQ:KRTX)  Shares Down 6.3%

This is a signal that KRTX's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

Karuna Therapeutics (KRTX, $208.09) RSI Indicator left the overbought zone on December 05, 2023

Karuna Therapeutics, Inc. (NASDAQ:KRTX  Get Free Report) has been given an average recommendation of Moderate Buy by the twelve research firms that are currently covering the...

Karuna Therapeutics, Inc. (NASDAQ:KRTX) Receives Average Recommendation of "Moderate Buy" from Brokerages

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric and neurological conditions...

Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ('PureTech' or the 'Company'), a clinical-stage biotherapeutics company, noted today that its Founded Entity, Karuna Therapeutics...

PureTech Founded Entity Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Eli Lilly & Co (LLY Research Report), Karuna The...

Analysts Conflicted on These Healthcare Names: Eli Lilly & Co (LLY), Karuna Therapeutics (KRTX) and Masimo (MASI)

This is a Bearish indicator signaling KRTX's price could decline from here. Traders may explore shorting the stock or put options...

Karuna Therapeutics (KRTX, $168.09) Moving Average Convergence Divergence (MACD) Histogram turned negative on November 16, 2023

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ('PureTech' or the 'Company'), a clinical-stage biotherapeutics company, noted that its Founded Entity, Karuna Therapeutics (NASDAQ...

PureTech Founded Entity Karuna Therapeutics Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia

Karuna Therapeutics Inc (NASDAQ: KRTX) released results from its Phase 1b open-label, eight-week inpatient trial evaluating the effect of KarXT (xanomeline-trospium) on 24-hour ambulatory blood...

Karuna Therapeutics Says Its Antipsychotic Candidate Shows Favorable Cardiovascular Safety Profile In Schizophrenia Patients

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Notable Labs (NTBL Research Report) and Karuna The...

Analysts Are Bullish on These Healthcare Stocks: Notable Labs (NTBL), Karuna Therapeutics (KRTX)

Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. engages in business of research and development of therapies utilizing muscarinic cholinergic receptors to treat psychosis and cognitive impairment in numerous central nervous system disorders. The company was founded by Andrew Miller, Eric Elenko, and Peter Jeffrey Conn in July 2009 and is headquartered in Boston, MA.

Market Cap	$7.75B
Volume (M)	48,910.00
52-Wk High	$245.00
52-Wk Low	$158.38

KRTX Karuna Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals

Sentiment

Message Volume

Community